Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) and commun...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakota, Elizabeth A., Van Wart, Scott A., Trang, Michael, Tzanis, Evan, Bhavnani, Sujata M., Safir, M. Courtney, Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G., Rubino, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318031/
https://www.ncbi.nlm.nih.gov/pubmed/32340986
http://dx.doi.org/10.1128/AAC.02263-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318031/
https://www.ncbi.nlm.nih.gov/pubmed/32340986
http://dx.doi.org/10.1128/AAC.02263-19

Ejemplares similares